Prime Medicine, Inc.

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%
HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$567.14M
EPS-1.3500
P/E Ratio-2.33
Earnings Date08/06/2026

prme

Total Current Liabilities

Last Annual Value

37.45M

3-Year CAGR

12%

5-Year CAGR

14%

10-Year CAGR

18%

Prime Medicine, Inc.

Prime Medicine, Inc. Competitors Analysis of Total Current Liabilities

PRME · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
37.45M
-12.8%-8.4%N/A 
PROK logo
ProKidney Corp.
NASDAQ:PROK
30.74M
7.1%20.1%N/A
116.97M
49.1%39.1%35.9%
SEPN logo
Septerna, Inc.
NASDAQ:SEPN
86.93M
132.5%N/AN/A
37.02M
-16.4%9.4%21.9%
62.36M
22.6%33.8%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
11.91M
31.8%43.3%21.3%
44.92M
-19.9%-13.7%N/A
18.09M
5.7%38.0%N/A
92.81M
-19.1%-22.9%N/A
28.95M
24.3%N/AN/A
Prime Medicine, Inc.

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

Intrinsic Value
Current Price: $3.14